Somalogic, Incorporated

Somalogic Operating Co., Inc.

Edward N Brody

Michael Riel-Mehan

Larry Gold

David Sterling

Shintaro Kato

Larry M Gold

Dominic Zichi

Malti P Nikrad

Alex Ae Stewart

Rachel M Ostroff

Stephen Alaric Williams

Alex A E Stewart

Marty Stanton

Alex AE Stewart

Methods and computer methods used to assess an individual for the prediction of risk of developing a Cardiovascular (CV) Event over a 1 to 5 year period are provided. The methods employ at least two biomarkers selected from MMP12, angiopoietin-2, complement C7, cardiac troponin I, angiopoietin-related protein 4, CCL18/PARC, alpha-1-antichymotrypsin complex, GDF11 and alpha-2-antiplasmin, or GDF11 in combination with FSTL3. The methods are particularly useful in predicting CV events in patients who suffer from coronary heart disease (CHD).

Cardiovascular risk event prediction and uses thereof

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

Lung cancer biomarkers and uses thereof

Growing community of inventors

Boulder, CO, United States of America

Edward N Brody